Bezafibrate
Bezafibrate is a lipid-lowering medication belonging to the fibrate class, used to manage abnormal blood lipid levels, particularly high triglycerides and mixed hyperlipidaemia. It works by activating peroxisome proliferator-activated receptor alpha (PPAR-α), helping reduce triglyceride levels and improve cholesterol balance. The medicine is available as oral tablets, including modified-release formulations, and is generally prescribed alongside dietary changes, physical activity, and weight management. Common side effects include nausea, abdominal discomfort, diarrhoea, and skin rash. Important risks include muscle injury, rarely progressing to rhabdomyolysis, gallstone formation, and changes in liver or kidney function. Kidney function should be assessed for appropriate dosing, and caution is required when combining bezafibrate with statins because of the increased risk of muscle toxicity.
Bezafibrate was historically used as a respiratory medicine for the symptomatic management of certain respiratory conditions. Its former uses included:
is okay
The import of medicines into India is regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The regulatory requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished formulation, or an unapproved medicine intended for an individual patient's treatment.
Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Bezafibrate, subject to confirmation of its current regulatory status and eligibility for import into India.
The export of Bezafibrate from India is subject to applicable requirements under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and relevant export, customs, and destination-country regulations. Documentation requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished pharmaceutical formulation, or a medicine intended for a specific market. Export eligibility and destination-country requirements must be verified before shipment.
Primeera Healthcare Private Limited can provide pharmaceutical export documentation assistance, regulatory coordination, and shipping support for Bezafibrate, subject to confirmation of its export eligibility under applicable Indian regulations and the import requirements of the destination country.
If you have any questions or need any help, contact our Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
All Trademarks and Brands that appear on the website belong to their respective owners. Primeera Healthcare does not lay any claim on them; we only provide information.
